Related Articles

OBJECTIVES:Controlled ileal release budesonide and slow release mesalazine are both used to treat mild to moderate active Crohnâ€™s disease, although data show that budesonide is more effective in inducing remission. When comparing different treatment options, the effects of agents on...

Discusses research being done on the effectiveness of infliximab as a maintenance treatment in patients with Crohn's disease. Reference to study by S.B. Hanauer and colleagues published in the May 2002 issue of the journal 'Lancet'; Information on the study population; Administration of...

Presents a case of a patient with Crohn's disease. Use of prednisone for the initial treatment of the patient; Effect of using azathioprine; Hypersensitivity reaction to azathioprine; Occurrence of defervescence; Discontinued use of antibiotics and corticosteroids.

The article focuses on a study, according to which introducing sophisticated biologic therapies early in the course of treatment for Crohn's disease improves response to medication and reduces the need for surgery.

This article examines the efficacy of infliximab and other biologics used in the management of Crohn's disease. Data from the first major national registry of Crohn's disease patients compared the long-term safety profile of infliximab with standard treatments and found all other drugs similarly...

In this article, the author discusses the result of a study conducted in Leuven, Belgium to determine the efficacy on the use of infliximab in Crohn's disease. The result of the study shows that 614 patients, comprising of individual having luminal disease while 25 percent having fistulising...

The article focuses on a research in which researchers from the Virginia Polytechnic Institute & State University, Blacksburg, Virginia, have discovered important information on the efficacy of conjugated linoleic acid in treating Crohn's disease.

The article discusses the approval of natalizumab, a drug marketed as Tysabri, for the treatment of moderate-to-severe Crohn's disease (CD). The drug was approved on January 14, 2008, after positive results were indicated in the three randomized, double-blind controlled trials that were...